Cargando…

Loss of Circulating Exosomal miR-92b is a Novel Biomarker of Colorectal Cancer at Early Stage

Early diagnosis of colorectal cancer (CRC) is clinically critical but technically challenging, especially in a minimal-invasive way. Emerging evidence suggests that exosome-encapsulated microRNAs (miRNAs) is a kind of promising cancer biomarker. Here we investigated the predictive potential of exoso...

Descripción completa

Detalles Bibliográficos
Autores principales: Min, Li, Chen, Lei, Liu, Si, Yu, Yang, Guo, Qingdong, Li, Peng, Zhu, Shengtao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6775270/
https://www.ncbi.nlm.nih.gov/pubmed/31588188
http://dx.doi.org/10.7150/ijms.34540
_version_ 1783456206795309056
author Min, Li
Chen, Lei
Liu, Si
Yu, Yang
Guo, Qingdong
Li, Peng
Zhu, Shengtao
author_facet Min, Li
Chen, Lei
Liu, Si
Yu, Yang
Guo, Qingdong
Li, Peng
Zhu, Shengtao
author_sort Min, Li
collection PubMed
description Early diagnosis of colorectal cancer (CRC) is clinically critical but technically challenging, especially in a minimal-invasive way. Emerging evidence suggests that exosome-encapsulated microRNAs (miRNAs) is a kind of promising cancer biomarker. Here we investigated the predictive potential of exosomal miR-92b in plasma samples obtained from 114 participants [40 CRC, 22 colorectal adenomas (CA), 52 non-neoplasm controls (NC)] by RT-qPCR. We found that exosomal miR-92b level was significantly down-regulated in CRC patients compared with CA and NC patients, especially in CRC at stage II, regardless of lymph node metastasis and invasive depth. The AUC in distinguishing CRC, CA and NC from each other ranged from 0.631 to 0.793, while a higher AUC of 0.830 was achieved in differentiating CRC at clinical stage II/III from NC individuals. Additionally, a logistic model integrating miR-92b with age showed a significantly improved accuracy in distinguishing CRC patients from NC (AUC increased from 0.793 to 0.867). Taken together, our findings indicated that decreased expression of exosome-derived miR-92b in plasma is a promising biomarker for early detection of CRC.
format Online
Article
Text
id pubmed-6775270
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-67752702019-10-04 Loss of Circulating Exosomal miR-92b is a Novel Biomarker of Colorectal Cancer at Early Stage Min, Li Chen, Lei Liu, Si Yu, Yang Guo, Qingdong Li, Peng Zhu, Shengtao Int J Med Sci Research Paper Early diagnosis of colorectal cancer (CRC) is clinically critical but technically challenging, especially in a minimal-invasive way. Emerging evidence suggests that exosome-encapsulated microRNAs (miRNAs) is a kind of promising cancer biomarker. Here we investigated the predictive potential of exosomal miR-92b in plasma samples obtained from 114 participants [40 CRC, 22 colorectal adenomas (CA), 52 non-neoplasm controls (NC)] by RT-qPCR. We found that exosomal miR-92b level was significantly down-regulated in CRC patients compared with CA and NC patients, especially in CRC at stage II, regardless of lymph node metastasis and invasive depth. The AUC in distinguishing CRC, CA and NC from each other ranged from 0.631 to 0.793, while a higher AUC of 0.830 was achieved in differentiating CRC at clinical stage II/III from NC individuals. Additionally, a logistic model integrating miR-92b with age showed a significantly improved accuracy in distinguishing CRC patients from NC (AUC increased from 0.793 to 0.867). Taken together, our findings indicated that decreased expression of exosome-derived miR-92b in plasma is a promising biomarker for early detection of CRC. Ivyspring International Publisher 2019-08-14 /pmc/articles/PMC6775270/ /pubmed/31588188 http://dx.doi.org/10.7150/ijms.34540 Text en © The author(s) This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Research Paper
Min, Li
Chen, Lei
Liu, Si
Yu, Yang
Guo, Qingdong
Li, Peng
Zhu, Shengtao
Loss of Circulating Exosomal miR-92b is a Novel Biomarker of Colorectal Cancer at Early Stage
title Loss of Circulating Exosomal miR-92b is a Novel Biomarker of Colorectal Cancer at Early Stage
title_full Loss of Circulating Exosomal miR-92b is a Novel Biomarker of Colorectal Cancer at Early Stage
title_fullStr Loss of Circulating Exosomal miR-92b is a Novel Biomarker of Colorectal Cancer at Early Stage
title_full_unstemmed Loss of Circulating Exosomal miR-92b is a Novel Biomarker of Colorectal Cancer at Early Stage
title_short Loss of Circulating Exosomal miR-92b is a Novel Biomarker of Colorectal Cancer at Early Stage
title_sort loss of circulating exosomal mir-92b is a novel biomarker of colorectal cancer at early stage
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6775270/
https://www.ncbi.nlm.nih.gov/pubmed/31588188
http://dx.doi.org/10.7150/ijms.34540
work_keys_str_mv AT minli lossofcirculatingexosomalmir92bisanovelbiomarkerofcolorectalcanceratearlystage
AT chenlei lossofcirculatingexosomalmir92bisanovelbiomarkerofcolorectalcanceratearlystage
AT liusi lossofcirculatingexosomalmir92bisanovelbiomarkerofcolorectalcanceratearlystage
AT yuyang lossofcirculatingexosomalmir92bisanovelbiomarkerofcolorectalcanceratearlystage
AT guoqingdong lossofcirculatingexosomalmir92bisanovelbiomarkerofcolorectalcanceratearlystage
AT lipeng lossofcirculatingexosomalmir92bisanovelbiomarkerofcolorectalcanceratearlystage
AT zhushengtao lossofcirculatingexosomalmir92bisanovelbiomarkerofcolorectalcanceratearlystage